|1.||Pezzilli, Raffaele: 3 articles (12/2009 - 01/2006)|
|2.||Börjesson, A: 3 articles (06/2003 - 01/2000)|
|3.||Andersson, R: 3 articles (06/2003 - 01/2000)|
|4.||Fantini, Lorenzo: 2 articles (01/2006 - 01/2006)|
|5.||Andersson, Roland: 2 articles (05/2005 - 06/2002)|
|6.||Wang, Xiangdong: 2 articles (05/2005 - 06/2002)|
|7.||Sun, Zhengwu: 2 articles (05/2005 - 06/2002)|
|8.||Johnson, C D: 2 articles (09/2004 - 01/2001)|
|9.||Sun, Z: 2 articles (03/2002 - 01/2000)|
|10.||Wang, X: 2 articles (03/2002 - 01/2000)|
01/01/1996 - "In a double-blind, randomized, Phase II, clinical study of lexipafant in human acute pancreatitis, a clinical benefit was found, as indicated by a significant reduction in an organ failure score measured during 72 h of infusion. "
08/01/2001 - "These results suggest that Lexipafant may be useful in the treatment of mild pancreatitis after its clinical onset."
02/01/1999 - "Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis."
09/01/2004 - "A total of 290 patients with predicted severe acute pancreatitis previously studied in a trial of lexipafant, recruited from 78 hospitals through 18 centres in the UK. "
01/01/2002 - "Published clinical trials of lexipafant (BB-882) in acute pancreatitis were retrieved by MEDLINE, EM Base, and Science Citation Index. "
06/01/1996 - "To assess the anti-inflammatory action of lexipafant (BB-882), a platelet activating factor antagonist, in an animal model of acute colitis. "
06/01/1996 - "Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis."
03/01/2000 - "A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). "
01/01/2001 - "Systemic sepsis affected fewer patients in the lexipafant group (13/138 v 4/148; p=0.023). "
03/01/2000 - "A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis."
08/01/1998 - "The present study evaluated the effect of a PAF antagonist, lexipafant (an (S)-4-methyl-2[methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-benzene sulphonyl]-amino]pentanoic acid ethyl ester, BB-882; British Biotech Ltd.), on the potential prevention of gut barrier dysfunction, by measuring gut origin sepsis, bidirectional permeability of the intestinal barrier, and pancreatic capillary endothelial barrier integrity, in acute pancreatitis induced by intraductal infusion of 5% sodium taurodeoxycholate. "
01/01/2001 - "Lexipafant, at low or high dose, did not moderate lung injury after cardiopulmonary bypass and did not influence the duration of postoperative ventilation. "
08/01/1996 - "Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist."
03/01/2002 - "To investigate the potential therapeutic inhibition of platelet-activating factor in intestinal ischaemia-reperfusion associated pulmonary injury, by use of a potent platelet-activating factor-receptor antagonist, lexipafant. "
08/01/1996 - "The aim of this study was to determine whether acute lung injury was a feature of the microembolic model of pancreatitis in rats and to assess the therapeutic effect of lexipafant (BB-882), a potent platelet-activating factor antagonist, on the lung injury. "
|2.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|3.||Interleukin-1 (Interleukin 1)
|4.||Platelet Activating Factor
|5.||platelet activating factor receptor
|6.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)